Abstract
Purpose
Angiogenesis is an important part in tumor progression and intratumoral microvessel density (MVD) has proven a prognostic factor in several solid tumors. However, its value in prostate cancer is still unclear, especially in small biopsy samples. We evaluated the prognostic potential of MVD in a large, homogeneous cohort of prostate cancers and its correlation with other pathologic parameters.
Methods
We used a tissue microarray (TMA) containing samples of 3,261 prostatectomy specimens from patients with prostate cancer. MVD was determined by counting vessels in a blinded fashion after immunohistochemical staining with an antibody against CD31. The results were compared with pre- and postoperative clinical and pathological parameters and clinical follow-up data.
Results
MVD was higher in TMA spots containing cancer as compared to benign tissue (P < 0.001). There was no significant correlation of MVD with preoperative parameters, but with pathological T-classification and Gleason score (P < 0.001, each) of the prostatectomy specimens. Furthermore, a higher MVD correlated with tumor location in the peripheral zone (P = 0.01). Follow-up data were available for 1,521 patients. In a univariable analysis, an MVD of ≥36 per spot was a significant predictor of PSA recurrence after radical prostatectomy (P = 0.03). However, it failed to provide an independent prognostic factor when combined with standard predictors in a multivariable analysis.
Conclusions
MVD in prostate cancer is closely related to other factors contributing to tumor aggressiveness. However, the implementation of this parameter into routinely performed pathological reports does not seem to be warranted.
Similar content being viewed by others
References
Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261–276
Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9–19
Weidner N (1998) Tumor vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 184:119–122
Fox SB, Gatter KC, Harris AL (1996) Tumour angiogenesis. J Pathol 179:232–237
Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401–409
Silberman MA, Partin AW, Veltri RW, Epstein JI (1997) Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79:772–779
Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, Von Eschenbach AC (1994) Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44:869–875
Concato J, Jain D, Li WW, Risch HA, Uchio EM, Wells CK (2007) Molecular markers and mortality in prostate cancer. BJU Int 100:1259–1263
Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M (2007) Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 27:3651–3660
Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, McLaren CE, Li KT, Fruehauf JP (2001) Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 7:81–88
Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S (2000) Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 42:26–33
Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK (2009) Molecular markers and death from prostate cancer. Ann Intern Med 150:595–603
Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG (1998) Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 51:79–85
Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG (1999) Role of microvessel density in predicting recurrence in pathologic stage T3 prostatic adenocarcinoma. Urology 54:479–485
Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, de-la-Taille A, Katz AE, Olsson CA, Ennis RD (1999) Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 53:542–547
Di LG, De PS, Autorino R, De Laurentiis M, Mignogna C, D’Armiento M, Tortora G, De RG, D’Armiento M, De SM, Bianco AR, D’Armiento FP (2005) Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis 8:54–59
Offersen BV, Borre M, Sorensen FB, Overgaard J (2002) Comparison of methods of microvascular staining and quantification in prostate carcinoma: relevance to prognosis. APMIS 110:177–185
Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ (1996) Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48:47–57
Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72–79
Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi O-P, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249–2256
Rogatsch H, Hittmair A, Reissigl A, Mikuz G, Feichtinger H (1997) Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 182:205–210
Hsu S-M, Raine L, Fanger H (1981) Use of avidin–biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580
Mazumdar M, Glassman JR (2000) Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19:113–132
Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387
Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA (1994) Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73:678–687
Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R (2002) Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5:123–127
Borre M, Offersen BV, Nerstrom B, Overgaard J (1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78:940–944
Erbersdobler A, Augustin H, Schlomm T, Henke RP (2004) Prostate cancers in the transition zone. Part 1. Pathological aspects. BJU Int 94:1221–1225
Erbersdobler A, Fritz H, Schnöger S, Graefen M, Hammerer P, Huland H, Henke R-P (2002) Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 41:40–46
Noguchi M, Stamey TA, Neal JE, Yemoto CE (2000) An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 163:1751–1755
Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW (2000) Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:995–1000
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
A. Erbersdobler and H. Isbarn contributed equally to this work.
Rights and permissions
About this article
Cite this article
Erbersdobler, A., Isbarn, H., Dix, K. et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 28, 687–692 (2010). https://doi.org/10.1007/s00345-009-0471-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-009-0471-4